Recent Quotes (30 days)

You have no recent quotes
chg | %

Dechra Pharmaceuticals plc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

DPH 1,551.27 -2.73 (-0.18%)
price chart
Dechra� Pharmaceuticals PLC Trading Update
International specialist veterinary pharmaceuticals and related products business, Dechra Pharmaceuticals PLC (Dechra or the Company) (Stock Code: Full Listing (Pharmaceuticals): DPH) issues the following unaudited Trading Update covering the half year ...
Dechra revenues rise  Stock Market Wire
Dechra Pharmaceuticals PLC: Australian Acquisition-Apex Laboratories for A$55m
Dechra is pleased to announce that it has agreed terms to acquire the business and assets of Apex Laboratories Pty Ltd ('Apex'), a privately owned veterinary pharmaceutical company which manufactures, markets and sells branded non-proprietary ...
Dechra Pharmaceuticals PLC: Annual Results
Dechra is an international specialist veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide.
Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after ...  Motley Fool UK
Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for ...
Dechra Pharmaceuticals PLC (LSE: symbol DPH) announces the conditional acquisition of the entire share capital of Putney, Inc, a leading developer of generic companion animal pharmaceuticals in the US, based in Portland, Maine.
Latham Advises Pet Meds Maker Putney In $200M Dechra Sale  Law360 (subscription)
Are RhythmOne plc, Dechra Pharmaceuticals plc and Pagegroup plc 'buys' after ...
Also reporting today was Dechra Pharmaceuticals (LSE: DPH). Its trading in the most recent full year was strong, with revenue rising by 21%.
Dechra� Pharmaceuticals PLC: Trading Update & Notice of 2016 Annual Results  PR Newswire (press release)
Dechra Pharmaceuticals PLC: Half-Yearly Financial Report 2016
"All our business units are performing well, we are in the process of launching several new products, our international expansion plans are progressing as expected and we have made two strategic acquisitions.
Dechra Pharmaceuticals plc - Receive News & Ratings Daily
Dechra Pharmaceuticals plc logo Dechra Pharmaceuticals plc (LON:DPH) has been assigned a consensus rating of “Buy” from the eight brokerages that are covering the company.
Are GlaxoSmithKline plc, Dechra Pharmaceuticals plc & CareTech Holdings plc On ...
For example, Dechra (LSE: DPH) has been able to increase its earnings at a double-digit rate in each of the last three years, with it rising at an annualised rate of 23% during the period.
Should you be buying AstraZeneca plc, Alliance Pharma plc and Dechra ...
One of the major concerns of investors in AstraZeneca (LSE: AZN) in recent years has been its ability to pay dividends. That's because it has been subjected to a patent cliff, where a number of key drugs have come off-patent and with the company ...
Dechra� Pharmaceuticals PLC (Dechra or the Group) : Trading Update
The Board of Dechra Pharmaceuticals PLC (LSE:DPH), issues the following unaudited Trading Update ahead of the Group's half-year financial results for the period ended 31 December 2015, which will be announced on Monday, 22 February 2016.